S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
NYSE:AVNS

Avanos Medical - AVNS Stock Forecast, Price & News

$28.84
-0.08 (-0.28%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$28.58
$29.10
50-Day Range
$27.22
$31.75
52-Week Range
$19.32
$34.83
Volume
137,685 shs
Average Volume
254,139 shs
Market Capitalization
$1.34 billion
P/E Ratio
27.47
Dividend Yield
N/A
Price Target
$30.00

Avanos Medical MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
4.0% Upside
$30.00 Price Target
Short Interest
Bearish
2.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.73mentions of Avanos Medical in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
19.05%
From $1.68 to $2.00 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

833rd out of 1,002 stocks

Surgical Appliances & Supplies Industry

16th out of 20 stocks


AVNS stock logo

About Avanos Medical (NYSE:AVNS) Stock

Avanos Medical, Inc. is a medical technology company. It engages in delivering clinically superior medical device solutions and products to healthcare providers and patients. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.

Receive AVNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter.

AVNS Stock News Headlines

Is Avanos Medical (AVNS) Stock Undervalued Right Now?
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Alcon (ALC) Q4 Earnings Match Estimates, Margins Contract
What Makes Avanos Medical (AVNS) a New Buy Stock
Q4 2022 Avanos Medical Inc Earnings Call
Earnings Outlook For Avanos Medical
See More Headlines
Receive AVNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter.

AVNS Company Calendar

Last Earnings
2/21/2023
Today
3/28/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
4,044
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.00
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+4.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$50.50 million
Pretax Margin
7.95%

Debt

Sales & Book Value

Annual Sales
$820 million
Cash Flow
$2.73 per share
Book Value
$27.77 per share

Miscellaneous

Free Float
45,635,000
Market Cap
$1.34 billion
Optionable
Optionable
Beta
0.93

Key Executives

  • Joseph F. Woody
    Chief Executive Officer & Executive Director
  • Michael C. Greiner
    Chief Financial & Transformation Officer, SVP
  • Lee Burnes
    Senior VP-Global Research & Development
  • Michelle Scharfenberg
    Chief Ethics & Compliance Officer, Senior VP
  • William D. Haydon
    Senior VP & General Manager-Pain Franchise













AVNS Stock - Frequently Asked Questions

Should I buy or sell Avanos Medical stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AVNS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVNS, but not buy additional shares or sell existing shares.
View AVNS analyst ratings
or view top-rated stocks.

What is Avanos Medical's stock price forecast for 2023?

2 brokerages have issued 1-year price targets for Avanos Medical's stock. Their AVNS share price forecasts range from $28.00 to $34.00. On average, they anticipate the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 4.0% from the stock's current price.
View analysts price targets for AVNS
or view top-rated stocks among Wall Street analysts.

How have AVNS shares performed in 2023?

Avanos Medical's stock was trading at $27.06 on January 1st, 2023. Since then, AVNS shares have increased by 6.6% and is now trading at $28.84.
View the best growth stocks for 2023 here
.

Are investors shorting Avanos Medical?

Avanos Medical saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,200,000 shares, an increase of 13.2% from the February 28th total of 1,060,000 shares. Based on an average daily volume of 244,500 shares, the short-interest ratio is presently 4.9 days. Approximately 2.6% of the shares of the stock are short sold.
View Avanos Medical's Short Interest
.

When is Avanos Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our AVNS earnings forecast
.

How were Avanos Medical's earnings last quarter?

Avanos Medical, Inc. (NYSE:AVNS) announced its quarterly earnings data on Tuesday, February, 21st. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.12. The firm had revenue of $217.50 million for the quarter, compared to analysts' expectations of $217.30 million. Avanos Medical had a trailing twelve-month return on equity of 6.13% and a net margin of 6.07%. The business's revenue for the quarter was up 12.5% on a year-over-year basis. During the same period last year, the firm posted $0.46 EPS.

What guidance has Avanos Medical issued on next quarter's earnings?

Avanos Medical issued an update on its FY 2023 earnings guidance on Tuesday, February, 21st. The company provided earnings per share (EPS) guidance of $1.60-$1.80 for the period, compared to the consensus EPS estimate of $1.68. The company issued revenue guidance of -.

What is Joseph F. Woody's approval rating as Avanos Medical's CEO?

32 employees have rated Avanos Medical Chief Executive Officer Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among the company's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Avanos Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Honeywell International (HON), Pfizer (PFE), Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA).

What is Avanos Medical's stock symbol?

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Who are Avanos Medical's major shareholders?

Avanos Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (6.22%), RGM Capital LLC (5.71%), Macquarie Group Ltd. (3.52%), Neuberger Berman Group LLC (1.88%), Geode Capital Management LLC (1.82%) and Charles Schwab Investment Management Inc. (1.44%). Insiders that own company stock include Gary Blackford and Patrick J Oleary.
View institutional ownership trends
.

How do I buy shares of Avanos Medical?

Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avanos Medical's stock price today?

One share of AVNS stock can currently be purchased for approximately $28.84.

How much money does Avanos Medical make?

Avanos Medical (NYSE:AVNS) has a market capitalization of $1.34 billion and generates $820 million in revenue each year. The company earns $50.50 million in net income (profit) each year or $1.05 on an earnings per share basis.

How many employees does Avanos Medical have?

The company employs 4,044 workers across the globe.

How can I contact Avanos Medical?

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The official website for the company is avanos.com. The company can be reached via phone at (844) 428-2667 or via email at investor.relations@avanos.com.

This page (NYSE:AVNS) was last updated on 3/29/2023 by MarketBeat.com Staff